KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Payables (2018 - 2025)

Aurinia Pharmaceuticals' Payables history spans 7 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Payables fell 36.13% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, down 36.13%, while the annual FY2025 figure was $3.3 million, 36.13% down from the prior year.
  • Payables reached $3.3 million in Q4 2025 per AUPH's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $56.8 million in Q3 2024 to a low of $2.2 million in Q3 2025.
  • Average Payables over 5 years is $28.4 million, with a median of $32.4 million recorded in 2022.
  • Peak YoY movement for Payables: skyrocketed 82.7% in 2022, then crashed 96.1% in 2025.
  • A 5-year view of Payables shows it stood at $34.9 million in 2021, then increased by 14.43% to $40.0 million in 2022, then tumbled by 89.18% to $4.3 million in 2023, then rose by 19.88% to $5.2 million in 2024, then tumbled by 36.13% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Payables are $3.3 million (Q4 2025), $2.2 million (Q3 2025), and $3.3 million (Q2 2025).